Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rubin Lubomirov

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Clinical Chemistry and Laboratory Medicine|March 12, 2010
Genetic polymorphisms of CYP1A2, CYP3A4, CYP3A5, pregnane/steroid X receptor and constitutive androstane receptor in 207 healthy Spanish volunteersPaloma Oliver, Rubin Lubomirov, Antonio Carcas
Pharmacogenomics|June 15, 2007
ADME pathway approach for pharmacogenetic studies of anti-HIV therapyRubin Lubomirov, Chantal Csajka, Amalio Telenti
Enfermedades Infecciosas Y Microbiologia Clinica|December 17, 2008
[General concepts and study methods in pharmacogenetics]Rubin Lubomirov, Amalio Telenti, Margalida Rotger
Journal of Clinical Pharmacology|April 29, 2021
Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With LurbinectedinCarlos Fernández-Teruel, Rubin Lubomirov, Salvador Fudio
Cancer Chemotherapy and Pharmacology|November 5, 2021
Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancerCarlos Fernández-Teruel, Salvador Fudio, Rubin Lubomirov
Frontiers in Oncology|July 3, 2023
A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS StudySalvador Fudio, Laura Pérez-Ramos, Eduardo Asín-Prieto, et al.
Clinical Pharmacokinetics|August 10, 2018
Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with CancerCarlos Fernandez-Teruel, Ignacio Gonzalez, Iñaki F Trocóniz, et al.
European Journal of Clinical Pharmacology|April 17, 2003
Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefitsJorge Gomez Cerezo, Rubin Lubomirov Hristov, Antonio J Carcas Sansuán, et al.
Clinical and Translational Science|March 27, 2025
CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor LurbinectedinRubin Lubomirov, Laura Pérez-Ramos, Salvador Fudio, et al.
Experimental and Clinical Psychopharmacology|October 20, 2017
Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapyAnaïs Glatard, Maria Dobrinas, Mehdi Gholamrezaee, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Clinical Chemistry and Laboratory Medicine|March 12, 2010
Genetic polymorphisms of CYP1A2, CYP3A4, CYP3A5, pregnane/steroid X receptor and constitutive androstane receptor in 207 healthy Spanish volunteersPaloma Oliver, Rubin Lubomirov, Antonio Carcas
Pharmacogenomics|June 15, 2007
ADME pathway approach for pharmacogenetic studies of anti-HIV therapyRubin Lubomirov, Chantal Csajka, Amalio Telenti
Enfermedades Infecciosas Y Microbiologia Clinica|December 17, 2008
[General concepts and study methods in pharmacogenetics]Rubin Lubomirov, Amalio Telenti, Margalida Rotger
Journal of Clinical Pharmacology|April 29, 2021
Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With LurbinectedinCarlos Fernández-Teruel, Rubin Lubomirov, Salvador Fudio
Cancer Chemotherapy and Pharmacology|November 5, 2021
Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancerCarlos Fernández-Teruel, Salvador Fudio, Rubin Lubomirov
Frontiers in Oncology|July 3, 2023
A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS StudySalvador Fudio, Laura Pérez-Ramos, Eduardo Asín-Prieto, et al.
Clinical Pharmacokinetics|August 10, 2018
Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with CancerCarlos Fernandez-Teruel, Ignacio Gonzalez, Iñaki F Trocóniz, et al.
European Journal of Clinical Pharmacology|April 17, 2003
Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefitsJorge Gomez Cerezo, Rubin Lubomirov Hristov, Antonio J Carcas Sansuán, et al.
Clinical and Translational Science|March 27, 2025
CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor LurbinectedinRubin Lubomirov, Laura Pérez-Ramos, Salvador Fudio, et al.
Experimental and Clinical Psychopharmacology|October 20, 2017
Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapyAnaïs Glatard, Maria Dobrinas, Mehdi Gholamrezaee, et al.
Pageof 4